bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2010.
Asia
Europe, Middle East, Africa
North America
bioMérieux - 2010 Business Review
19 January, 2011
bioMérieux Expands Customer Services Offer, Appointing James P. Whelan as Executive Vice President, Commercial Services
04 January, 2011
A world leader in in vitro diagnostics, bioMérieux announces the appointment of James P. Whelan as Executive Vice President of Commercial Services. In this newly created role, he will be responsible for reinforcing bioMérieux’s global service offering. This enhanced offering will include expanded customer lab audits, laboratory accreditation support and comprehensive scientific training programs.
Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis
21 December, 2010
Sepsis progresses quickly, yet rapid test is still largely unavailable in the U.S.
bioMérieux Restructures its Clinical Culture Media Business in North America and Announces the Closing of its Portland, OR Plant
01 December, 2010
bioMérieux announced today that, as part of a restructuring of its culture media business in the U.S. and Canada, it will phase out the manufacturing of its routine prepared media for clinical applications and will transfer the production of all other products manufactured at its Portland, Oregon site to other locations.
bioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
04 November, 2010
Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012 bioMérieux gains exclusive rights in microbiology bioMérieux takes equity stake in Biocartis
bioMérieux, Inc. Issues Urgent Product Correction for VITEK® 2 Gram Negative Susceptibility Cards Containing Piperacillin/Tazobactam
27 October, 2010
bioMérieux, Inc. on September 16, 2010, initiated a worldwide voluntary product correction of VITEK® 2 Gram Negative Susceptibility Cards containing the antibiotic Piperacillin/Tazobactam (TZP❷).
Business Review for the Nine Months Ended September 30, 2010
22 October, 2010
bioMérieux, a world leader in in vitro diagnostics, today released its business review for the nine months ended September 30, 2010.
bioMérieux Gains International Approval for its Automated "Next Day" Solution: VIDAS® Listeria Xpress
15 October, 2010
AOAC Official MethodsSM approval adds new level of confidence for food safety testing
2010 First-Half Review
06 September, 2010
The Board of Directors of bioMérieux, a global leader in the field of in vitro diagnostics, met on Friday, September 3, 2010 to approve the Group’s consolidated financial statements for the six months ended June 30, 2010. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors, who had performed a limited review of the financial statements.
bioMérieux to Host International Food Safety Symposium to Address Safety Issues Related to Food Supply
02 August, 2010
Ninth Annual Scientific Symposium to be held at the International Association for Food Protection’s (IAFP) 2010 Annual Meeting